Why cardio-rheumatology?

European Heart Journal - Cardiovascular Pharmacotherapy · Published 2026-06-26 · DOI 10.1093/ehjcvp/pvag045

Free full text

Authors (3)

Anne Grete Semb, Eirik Ikdahl, Anne Kerola

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Semb, A., Ikdahl, E., Kerola, A. (2026). Why cardio-rheumatology?. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvag045

Related articles

• Beta-blockers after myocardial infarction: time to change the guidelines · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• Why does research integrity affect us all? · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• Aspirin may take a back row seat for non-ST-segment elevation acute coronary syndrome after percutaneous coronary intervention · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• Innovation and constraints in cardiovascular pharmacotherapy · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• VESALIUS keeps revolutionizing medicine: the case of evolocumab in primary prevention · European Heart Journal - Cardiovascular Pharmacotherapy · 2025 · Same journal
• Effect of beta blockers in acute and chronic coronary syndromes without reduced ejection fraction: a landmark analysis from the REBOOT trial · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• Real-world evidence of finerenone in Type 2 diabetes: addressing confounding and follow-up duration · European Heart Journal - Cardiovascular Pharmacotherapy · 2025 · Same journal
• Different aspects of myocardial intervention and pharmacological treatment · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• Beyond the review: additional non-oncologic drugs with clinically significant cardiovascular effects · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• Management of dyslipidaemia in patients with comorbidities: facing the challenge: type 2 diabetes mellitus · European Heart Journal - Cardiovascular Pharmacotherapy · 2025 · Same journal